Abstract
The adoptive transfer of human regulatory T cells (Tregs) in transplantation offers an attractive therapeutic alternative in the current struggle to improve long-term outcomes. CD4+CD25+FOXP3+ (Tregs) play an important role in immunoregulation and have been shown in animal models to promote transplantation tolerance. Phase I trials in bone marrow transplantation and type I diabetes have already shown that ex vivo expanded Tregs have an excellent safety profile, which is encouraging for their current use as novel therapeutic strategies in solid organ transplantation. As such, the practicality of Treg adoptive cell therapy is now widely accepted, provided that tailor-made clinical grade procedures for the isolation and ex vivo cell handling are available. Here we present a review on the concept of Treg biology and heterogeneity, the desire to isolate and expand a functionally superior Treg population and report on the effect of differing culture conditions. We will summarise some of the protocols used for their ex vivo expansion, outline the clinical trials to date and discuss the future directions of Treg cell therapy. ©
| Original language | English |
|---|---|
| Title of host publication | Technological Advances in Organ Transplantation |
| Publisher | Springer International Publishing Switzerland |
| Pages | 133-150 |
| Number of pages | 18 |
| ISBN (Electronic) | 9783319621425 |
| ISBN (Print) | 9783319621418 |
| DOIs | |
| Publication status | Published - 23 May 2018 |
